Anixa Biosciences Inc (ANIX)

$3.20 -0.22 (-6.43%)
Market Cap 105.33M
Revenue (ttm) 0.00
Net Income (ttm) -12.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 226,200
Avg Vol 315,006
Day's Range N/A - N/A
Shares Out 32.92M
Stochastic %K 4%
Beta 0.49
Analysts Strong Sell
Price Target $10.33

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 708 9808
Address:
3150 Almaden Expressway, Suite 250, San Jose, United States
RatioRational
RatioRational Dec. 25 at 4:46 PM
$ANIX This ticker is entering a stage where execution quality will overshadow headline narratives. Sequential improvement must start appearing across core metrics. Visible traction across segments would strengthen the thesis. Future re‑rating depends on turning narrative into measurable outcomes.
1 · Reply
justiceforb_85
justiceforb_85 Dec. 23 at 5:19 AM
$ANIX look forward to info on CER-T program in ovarian cancer.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 22 at 11:46 PM
$ANIX Share Price: $3.39 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.71 – $0.86 Potential Upside: 74% ROI Time to Expiration: 206 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MQuick
MQuick Dec. 19 at 12:28 PM
$GANX there have been a few recent attacks on phase 1 bios $ANIX being one of them extremely similar to what happened to us. I think they are deliberate short attacks.
0 · Reply
TimRegan_WTR
TimRegan_WTR Dec. 18 at 7:17 PM
$ANIX
0 · Reply
4Reel
4Reel Dec. 18 at 6:18 PM
$ANIX absolutely disgusting what the company did and had 5 or 6 weeks to prepare for the data that led to tgeir 2 worst days of the year in a row. And their worst day in 5 years. A lot of people got crushed here. Hard to be positive when a catalydt like they ahd with no information or follow through killed their stock
0 · Reply
research_WTR
research_WTR Dec. 18 at 4:42 PM
Check out Robert Sassoon's management series, including a recap and transcript from his recent fireside chat with Anixa Biosciences, Inc. Chairman & CEO Dr. Amit Kumar. This conversation can be accessed on demand. Links are available in the full report! https://www.watertowerresearch.com/doc?docID=MS_ANIX_12162025 $ANIX #AnixaBiosciences #Phase1 #Trial #Healthcare #BreastCancer #Oncology #SmallCap #Stocks #Investing
0 · Reply
DARKP00L
DARKP00L Dec. 16 at 8:10 PM
$ANIX the market is buzzing about this stock. Expect possible price changes!
1 · Reply
bioinvestorrr
bioinvestorrr Dec. 16 at 7:38 PM
$ANIX hmm
0 · Reply
BagODonuts
BagODonuts Dec. 16 at 5:11 PM
$ANIX Well now the the MNPI on trial results are out the insiders are free to buy / sell at will.
0 · Reply
Latest News on ANIX
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

Dec 15, 2025, 8:45 AM EST - 13 days ago

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Dec 11, 2025, 6:02 PM EST - 16 days ago

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

Dec 10, 2025, 9:00 AM EST - 18 days ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript

Nov 17, 2025, 6:17 PM EST - 5 weeks ago

Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Nov 17, 2025, 8:15 AM EST - 5 weeks ago

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

Nov 12, 2025, 11:00 AM EST - 6 weeks ago

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Nov 12, 2025, 9:00 AM EST - 6 weeks ago

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

Nov 10, 2025, 10:30 AM EST - 6 weeks ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Nov 5, 2025, 8:55 AM EST - 7 weeks ago

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

Oct 23, 2025, 8:45 AM EDT - 2 months ago

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Oct 20, 2025, 8:25 AM EDT - 2 months ago

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Oct 7, 2025, 8:30 AM EDT - 2 months ago

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Sep 22, 2025, 8:05 AM EDT - 3 months ago

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Sep 8, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:54 AM EDT - 4 months ago

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 9:13 AM EDT - 4 months ago

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Aug 20, 2025, 8:37 AM EDT - 4 months ago

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Aug 18, 2025, 9:00 AM EDT - 4 months ago

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Aug 12, 2025, 8:05 AM EDT - 4 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Aug 8, 2025, 9:15 AM EDT - 5 months ago

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Aug 4, 2025, 8:45 AM EDT - 5 months ago

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Jul 30, 2025, 8:15 AM EDT - 5 months ago

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Jul 24, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Anixa Biosciences: Oncology Platform With Asymmetric Upside

Jul 15, 2025, 3:49 PM EDT - 5 months ago

Anixa Biosciences: Oncology Platform With Asymmetric Upside

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jul 9, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 23, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 20, 2025, 7:30 AM EDT - 6 months ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 10, 2025, 7:00 AM EDT - 7 months ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Jun 9, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Jun 3, 2025, 7:25 AM EDT - 7 months ago

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

Jun 2, 2025, 7:00 AM EDT - 7 months ago

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

May 19, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 12, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Apr 30, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Apr 14, 2025, 8:00 AM EDT - 9 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Apr 9, 2025, 8:00 AM EDT - 9 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Apr 1, 2025, 8:00 AM EDT - 9 months ago

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Mar 25, 2025, 8:00 AM EDT - 9 months ago

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Mar 24, 2025, 8:00 AM EDT - 9 months ago

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Mar 17, 2025, 8:00 AM EDT - 10 months ago

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Mar 10, 2025, 8:30 AM EDT - 10 months ago

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Mar 3, 2025, 8:00 AM EST - 10 months ago

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Feb 26, 2025, 8:00 AM EST - 10 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Feb 25, 2025, 7:30 AM EST - 10 months ago

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Feb 24, 2025, 8:00 AM EST - 10 months ago

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Feb 18, 2025, 8:00 AM EST - 11 months ago

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

Feb 14, 2025, 7:00 AM EST - 11 months ago

Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum

Feb 11, 2025, 8:30 AM EST - 11 months ago

Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum

Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention

Feb 4, 2025, 8:30 AM EST - 11 months ago

Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention

Anixa Biosciences CEO Provides Letter to Shareholders

Jan 21, 2025, 8:30 AM EST - 1 year ago

Anixa Biosciences CEO Provides Letter to Shareholders

RatioRational
RatioRational Dec. 25 at 4:46 PM
$ANIX This ticker is entering a stage where execution quality will overshadow headline narratives. Sequential improvement must start appearing across core metrics. Visible traction across segments would strengthen the thesis. Future re‑rating depends on turning narrative into measurable outcomes.
1 · Reply
justiceforb_85
justiceforb_85 Dec. 23 at 5:19 AM
$ANIX look forward to info on CER-T program in ovarian cancer.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 22 at 11:46 PM
$ANIX Share Price: $3.39 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.71 – $0.86 Potential Upside: 74% ROI Time to Expiration: 206 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MQuick
MQuick Dec. 19 at 12:28 PM
$GANX there have been a few recent attacks on phase 1 bios $ANIX being one of them extremely similar to what happened to us. I think they are deliberate short attacks.
0 · Reply
TimRegan_WTR
TimRegan_WTR Dec. 18 at 7:17 PM
$ANIX
0 · Reply
4Reel
4Reel Dec. 18 at 6:18 PM
$ANIX absolutely disgusting what the company did and had 5 or 6 weeks to prepare for the data that led to tgeir 2 worst days of the year in a row. And their worst day in 5 years. A lot of people got crushed here. Hard to be positive when a catalydt like they ahd with no information or follow through killed their stock
0 · Reply
research_WTR
research_WTR Dec. 18 at 4:42 PM
Check out Robert Sassoon's management series, including a recap and transcript from his recent fireside chat with Anixa Biosciences, Inc. Chairman & CEO Dr. Amit Kumar. This conversation can be accessed on demand. Links are available in the full report! https://www.watertowerresearch.com/doc?docID=MS_ANIX_12162025 $ANIX #AnixaBiosciences #Phase1 #Trial #Healthcare #BreastCancer #Oncology #SmallCap #Stocks #Investing
0 · Reply
DARKP00L
DARKP00L Dec. 16 at 8:10 PM
$ANIX the market is buzzing about this stock. Expect possible price changes!
1 · Reply
bioinvestorrr
bioinvestorrr Dec. 16 at 7:38 PM
$ANIX hmm
0 · Reply
BagODonuts
BagODonuts Dec. 16 at 5:11 PM
$ANIX Well now the the MNPI on trial results are out the insiders are free to buy / sell at will.
0 · Reply
stockobserver51
stockobserver51 Dec. 16 at 3:58 PM
$ANIX The director should have done this by December 10th as a sign of good news. Now, after the share price has plummeted by almost 35%, this action is being seen as compensation for poor communication.
0 · Reply
SCUBus
SCUBus Dec. 16 at 3:11 PM
$ANIX Director Titterton exercised options to buy 16,000 shares yesterday (12/15/2025). He now owns 969,334 shares. That doesn't reflect all the shares he has previously given to his children.
1 · Reply
Itinerant
Itinerant Dec. 16 at 3:07 PM
$ANIX Nice Director buy reported today.
1 · Reply
Pedelco
Pedelco Dec. 16 at 3:02 PM
$ANIX bounce to 5$ till 🎄🍀
0 · Reply
ChessHere
ChessHere Dec. 16 at 2:56 PM
$ANIX As for joint ventures/partnerships, Amit has been promising that the whole 7 years I have been a bag holder - shame on me for believing him. If there ever was a person guilty of FOMO I am sure I was at the head of the line. And once again all I hear is "we are talking to companies"... well as it turns out, talk is cheap.
0 · Reply
ChessHere
ChessHere Dec. 16 at 2:52 PM
$ANIX I give up! These f'ing clowns are making millions off the rest of us without ever delivering on anything. Amit is great at telling us what we want to hear while having his hand in our back pocket. Did ANYONE tell us about the 4 patients that had their cancer return?? NO!! We had to hear about it at the conference from the Cleveland Clinic - at least they were honest. Right up to a few days before the data release Amit was singing the praises on how good the results were with not once telling us about the vaccine failures (hmmm... borderline fraud?). Even Tailwinds has given up on them.
1 · Reply
jshdn
jshdn Dec. 15 at 11:50 PM
$ANIX i would like to know more about the four people who got cancer reoccurring during the trial, I guess despite the shot? Beyond that, his interview was very good today and I share his optimism.
0 · Reply
Pokemon69
Pokemon69 Dec. 15 at 11:08 PM
$ANIX Would this shit ever bounce back?
1 · Reply
stockobserver51
stockobserver51 Dec. 15 at 7:43 PM
$ANIX This is an unbelievable disregard for investors.
1 · Reply
stockobserver51
stockobserver51 Dec. 15 at 7:26 PM
$ANIX Why would you take a company public if you have no interest in investors or stocks? That's an unbelievable statement. And that's exactly how the stock price reflects that.
0 · Reply
TDMF123
TDMF123 Dec. 15 at 7:03 PM
$ANIX Based on that chat, the CEO is a medical professional first, CEO second. Essentially, money is not his driving factor nor are stock price fluctuations. The stock is simply a tool for them to achieve their ultimate goal: An approved Vaccine. If there was ever a company that embodied the word Patience. This is it. Expect some type of joint venture/ partnership news sometime in mid 2026 if initial phase two data roll outs are positive. In a strange way, I’m more comfortable with my investment today. JMHO. God speed everyone
0 · Reply
SCUBus
SCUBus Dec. 15 at 6:24 PM
$ANIX Phase II will be an open trial, meaning results will be reflected as it goes along rather than waiting until the end. Planning for a test group of 80 - 100 women. Phase II to start in coming year 2026 with results starting shortly thereafter. CEO Amit Kumar said he expects results to be FANTASTIC. A CEO would not say that publicly unless he knows something.
2 · Reply